Skip to content

AIM Market Roundup: Genincode, Silver Bullet, Focusrite

AIM Market Roundup: Genincode, Silver Bullet, Focusrite

The theme seems to be one of sitting on hands for many investors right now as that pivotal Fed meeting and press conference creep ever closer. The AIM All Share Index was very much in this zone today, adding less than a quarter of a point to close at 767.67.

  • Genincode +126%
  • Silver Bullet +24%
  • Focusrite +15%
  • Manolete -20%
  • Tertiary Minerals -17%

Genincode LON:GENI was the day’s best performer, with the share price in the cardiac genetics diagnostics company adding 129% by the bell. There’s no news here but volumes were significantly elevated and the company is attempting to navigate an FDA approvals process. Is an update imminent?


Silver Bullet Data Services LON:SBDS was 24% higher following news of an NED appointment. The new appointee is seen as having significant experience in leading high-growth digital and media businesses. The stock also saw significantly elevated volumes of trade – expectations are clearly riding high.

Focusrite LON:TUNE gets the notable mention, up 15%. That comes off the back of a trading update which saw increased revenue despite difficult trading conditions. Net debt has also improved.

Manolete Partners LON:MANO was the biggest faller, off 20%. An AGM update posted this morning reiterated the fact that this is far from being a commodity business, with comparatively low frequency, potentially large value cases being handled. The year on year performance shows a smaller number of high value cases being settled.

Tertiary Minerals LON:TYM was the second biggest faller, off 17%. The company continues to give back gains following recent positive mining news. Volumes were elevated but a wide spread was being quoted at the close, barely below the sell-off.

Share this article

Invest with these platforms

Interactive Brokers eToro Charles Stanley Hargreaves Lansdown IG
Interactive Brokers eToro Charles Stanley
Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

ARK
Pepperstone
aberdeen
FP Markets

eToro
CME Group
WisdomTree
Schroders

Back To Top